Background Atrial fibrillation is one of the most common sustained cardiac arrhythmias and is associated with a high risk of ischemic stroke, thromboembolic complications, and mortality. Direct oral anticoagulants are widely used for stroke prevention in patients with atrial fibrillation and are currently considered standard therapy. However, the effectiveness of this therapy largely depends on long term patient adherence and persistence with treatment, since missed doses or premature discontinuation reduce the level of anticoagulant protection. Aims The aim of this review was to summarize current evidence on adherence and persistence to direct oral anticoagulant therapy in atrial fibrillation, to compare these indicators between individual agents, and to analyze factors influencing treatment adherence and associated clinical outcomes. Methods The study was conducted as a narrative literature review. Publications were searched in the PubMed and Google Scholar databases. Studies published between 2015 and 2025 were considered. Titles and abstracts were screened followed by full text assessment of potentially relevant studies. A total of 57 publications addressing treatment adherence, persistence, dosing practices, and clinical outcomes of direct oral anticoagulants in patients with atrial fibrillation were analyzed. Due to substantial heterogeneity of study designs and outcome measures, a qualitative synthesis of the evidence was performed without quantitative meta analysis. The comparative analysis focused on rivaroxaban, dabigatran, and apixaban. Edoxaban was not analyzed separately because of limited and heterogeneous data in the available studies. Results Analysis of published observational studies demonstrates substantial variability in adherence and treatment persistence among different direct oral anticoagulants. In most cohort studies higher adherence is observed with rivaroxaban and apixaban compared with dabigatran. Several studies also report longer treatment persistence with apixaban during long term follow up. These differences are partly explained by dosing regimens, treatment tolerability, and the frequency of adverse effects. Incorrect dosing of anticoagulants represents a common problem in clinical practice and is observed in a considerable proportion of patients, with underdosing occurring more frequently than overdosing. Deviations from recommended dosing regimens are associated with poorer clinical outcomes, including increased risk of thromboembolic complications. Treatment adherence is also influenced by multiple factors such as patient age, polypharmacy, complexity of dosing regimens, and socioeconomic conditions of medical care. Conclusions Adherence and persistence to direct oral anticoagulant therapy in patients with atrial fibrillation differ substantially between individual drugs and patient populations. Lower adherence is more frequently observed with dabigatran, whereas factor Xa inhibitors, particularly rivaroxaban and apixaban, demonstrate higher levels of treatment adherence in most studies. Incorrect dosing and clinical factors affecting treatment continuation represent important determinants of anticoagulant therapy effectiveness. Optimization of therapy requires individualized drug selection, appropriate dose adjustment according to renal function and clinical guidelines, and the implementation of strategies aimed at improving long term adherence to anticoagulant therapy.